Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Cabozantinib vs Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
jRCT2080224017Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Nivolumab + Cabozantinib with Sunitinib (2 arms). Started Aug 2018; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080224017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224017.